The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The industry rank for PROCEPT BioRobotics's 14-Day RSI or its related term are showing as below:
MEX:PRCT's 14-Day RSI is ranked better than 81.49% of 870
companies
in the Medical Devices & Instruments industry
Industry Median: 47.555
vs MEX:PRCT: 4.76
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
PROCEPT BioRobotics 14-Day RSI Related Terms
MEX:PRCT vs ENOV, INSP, IRMD: 14-Day RSI Comparison
For the Medical Devices subindustry, PROCEPT BioRobotics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PROCEPT BioRobotics 14-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PROCEPT BioRobotics's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where PROCEPT BioRobotics's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PROCEPT BioRobotics (MEX:PRCT) has a 14-Day RSI of 4.76 as of Jul. 04, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on PROCEPT BioRobotics and its competitors. According to the industry distribution chart, PROCEPT BioRobotics ranks #161 out of 870 companies in the Medical Devices & Instruments industry, placing it in the top 18.5%.
Is PROCEPT BioRobotics' 14-Day RSI too high?
PROCEPT BioRobotics' current 14-Day RSI is 4.76. The Medical Devices & Instruments industry median 14-Day RSI is 47.56. PROCEPT BioRobotics' value of 4.76 is 90% below this industry median. Based on the distribution chart, PROCEPT BioRobotics ranks #161 out of 870 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, PROCEPT BioRobotics has a GF Score™ of 54/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PROCEPT BioRobotics' 14-Day RSI compare to ENOV and INSP?
According to the Medical Devices & Instruments industry distribution chart, PROCEPT BioRobotics ranks #161 out of 870 companies for 14-Day RSI. This places PROCEPT BioRobotics in the top 19% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 47.56. PROCEPT BioRobotics' value of 4.76 is 90% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Devices & Instruments company?
The median 14-Day RSI among Medical Devices & Instruments companies is 47.56, based on 870 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PROCEPT BioRobotics's current 14-Day RSI of 4.76 is 90% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on PROCEPT BioRobotics and its competitors. For the Medical Devices & Instruments industry, the median 14-Day RSI is 47.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PROCEPT BioRobotics's current 14-Day RSI is 4.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROCEPT BioRobotics stock overvalued right now?
Based on GuruFocus' analysis, PROCEPT BioRobotics (MEX:PRCT) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,578.30, compared to a current price of MXN358.45 — trading 77.3% below its estimated fair value. The current 14-Day RSI is 4.76 and 90% below the Medical Devices & Instruments industry median of 47.56. PROCEPT BioRobotics' overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For PROCEPT BioRobotics (MEX:PRCT), the current 14-Day RSI is 4.76 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PROCEPT BioRobotics (MEX:PRCT) Overvalued in 2026?
Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued.
The current stock price of MXN358.45 is trading 77.3% below its estimated GF Value™ of MXN1,578.30.
GuruFocus considers PROCEPT BioRobotics to be Significantly Undervalued.
Key valuation signals for MEX:PRCT:
14-Day RSI: 4.76
GF Value™: MXN1,578.30 vs. price of MXN358.45 (77.3% below fair value)
Industry Position: 90% below the Medical Devices & Instruments median (#161 of 870)
No single metric tells the full story. See the MEX:PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
54GF Score
Get the complete analysis for MEX:PRCT
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:PRCT has been successfully added to your 